Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17

Masaki Kiga, Fumie Tanzawa, Shiho Iwasaki, Fumi Inaba, Kosaku Fujiwara, Hayato Iwadare, Tomoki Echigo, Yuji Nakamura, Tomoyuki Shibata, Kanae Suzuki, Isao Yasumatsu, Ayako Nakayama, Yukiko Sasazawa, Etsu Tashiro, Masaya Imoto, Shinichi Kurakata

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The mitogen-activated protein kinase (MAPK) signal pathway plays a central role in regulating tumor cell proliferation, survival, and differentiation. The components of this pathway, Ras/Raf/MEK/ERK, are frequently activated in human cancers. Targeting this pathway is considered to be a promising anticancer strategy. In particular, MEK is an attractive drug target because of its high selectivity to ERK. We can expect potent growth inhibitory and proapoptotic effects by inhibiting MEK. Here, we report derivatives of N-[2-(2-chloro-4-iodo- phenylamino)-3,4-difluorophenyl]-methanesulfonamide as novel MEK1/2 inhibitors. Among these compounds, we found SMK-17 to be a potent MEK1/2 inhibitor with high aqueous solubility. The in-silico docking study suggested that SMK-17 is bound to an allosteric pocket of MEK1. The kinetic study and the kinase profiler analysis confirmed the allosteric nature of SMK-17. SMK-17 inhibited MEK1 kinase activity in a non-ATP-competitive manner and it was highly selective to MEK1 and 2. SMK-17 inhibited the growth of tumor cell lines in vitro. Especially, it seemed that cell lines harboring highly phosphorylated MEK1/2 and ERK1/2 were highly sensitive to SMK-17. Moreover, unlike previously reported MEK inhibitors, PD184352 or U0126, SMK-17 did not inhibit the phosphorylation of ERK5. In vivo, SMK-17 exhibited potent antitumor activity in animal models on oral administration. SMK-17 selectively blocked the MAPK pathway signaling without affecting other signal pathways, which resulted in significant antitumor efficacy without notable side effects. These findings suggest that SMK-17, an exquisitely selective, orally available MEK1/2 inhibitor, is a useful chemical biology tool for characterizing the function of MEK/MAPK signaling both in vitro and in vivo.

Original languageEnglish
Pages (from-to)119-130
Number of pages12
JournalAnti-Cancer Drugs
Volume23
Issue number1
DOIs
Publication statusPublished - 2012 Jan

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Mitogen-Activated Protein Kinases
Signal Transduction
Phosphotransferases
SMK-17
Growth
Tumor Cell Line
Computer Simulation
Solubility
Oral Administration
Cell Differentiation
Neoplasms
Cell Survival
Animal Models
Phosphorylation
Cell Proliferation
Cell Line
Pharmaceutical Preparations
In Vitro Techniques

Keywords

  • allosteric inhibition
  • antitumor activities
  • cell cycle arrest
  • kinase inhibitor
  • xenograft model

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Kiga, M., Tanzawa, F., Iwasaki, S., Inaba, F., Fujiwara, K., Iwadare, H., ... Kurakata, S. (2012). Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17. Anti-Cancer Drugs, 23(1), 119-130. https://doi.org/10.1097/CAD.0b013e32834c6a33

Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17. / Kiga, Masaki; Tanzawa, Fumie; Iwasaki, Shiho; Inaba, Fumi; Fujiwara, Kosaku; Iwadare, Hayato; Echigo, Tomoki; Nakamura, Yuji; Shibata, Tomoyuki; Suzuki, Kanae; Yasumatsu, Isao; Nakayama, Ayako; Sasazawa, Yukiko; Tashiro, Etsu; Imoto, Masaya; Kurakata, Shinichi.

In: Anti-Cancer Drugs, Vol. 23, No. 1, 01.2012, p. 119-130.

Research output: Contribution to journalArticle

Kiga, M, Tanzawa, F, Iwasaki, S, Inaba, F, Fujiwara, K, Iwadare, H, Echigo, T, Nakamura, Y, Shibata, T, Suzuki, K, Yasumatsu, I, Nakayama, A, Sasazawa, Y, Tashiro, E, Imoto, M & Kurakata, S 2012, 'Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17', Anti-Cancer Drugs, vol. 23, no. 1, pp. 119-130. https://doi.org/10.1097/CAD.0b013e32834c6a33
Kiga, Masaki ; Tanzawa, Fumie ; Iwasaki, Shiho ; Inaba, Fumi ; Fujiwara, Kosaku ; Iwadare, Hayato ; Echigo, Tomoki ; Nakamura, Yuji ; Shibata, Tomoyuki ; Suzuki, Kanae ; Yasumatsu, Isao ; Nakayama, Ayako ; Sasazawa, Yukiko ; Tashiro, Etsu ; Imoto, Masaya ; Kurakata, Shinichi. / Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17. In: Anti-Cancer Drugs. 2012 ; Vol. 23, No. 1. pp. 119-130.
@article{ad901aaa2b104a86b9118e1b20c0b72b,
title = "Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17",
abstract = "The mitogen-activated protein kinase (MAPK) signal pathway plays a central role in regulating tumor cell proliferation, survival, and differentiation. The components of this pathway, Ras/Raf/MEK/ERK, are frequently activated in human cancers. Targeting this pathway is considered to be a promising anticancer strategy. In particular, MEK is an attractive drug target because of its high selectivity to ERK. We can expect potent growth inhibitory and proapoptotic effects by inhibiting MEK. Here, we report derivatives of N-[2-(2-chloro-4-iodo- phenylamino)-3,4-difluorophenyl]-methanesulfonamide as novel MEK1/2 inhibitors. Among these compounds, we found SMK-17 to be a potent MEK1/2 inhibitor with high aqueous solubility. The in-silico docking study suggested that SMK-17 is bound to an allosteric pocket of MEK1. The kinetic study and the kinase profiler analysis confirmed the allosteric nature of SMK-17. SMK-17 inhibited MEK1 kinase activity in a non-ATP-competitive manner and it was highly selective to MEK1 and 2. SMK-17 inhibited the growth of tumor cell lines in vitro. Especially, it seemed that cell lines harboring highly phosphorylated MEK1/2 and ERK1/2 were highly sensitive to SMK-17. Moreover, unlike previously reported MEK inhibitors, PD184352 or U0126, SMK-17 did not inhibit the phosphorylation of ERK5. In vivo, SMK-17 exhibited potent antitumor activity in animal models on oral administration. SMK-17 selectively blocked the MAPK pathway signaling without affecting other signal pathways, which resulted in significant antitumor efficacy without notable side effects. These findings suggest that SMK-17, an exquisitely selective, orally available MEK1/2 inhibitor, is a useful chemical biology tool for characterizing the function of MEK/MAPK signaling both in vitro and in vivo.",
keywords = "allosteric inhibition, antitumor activities, cell cycle arrest, kinase inhibitor, xenograft model",
author = "Masaki Kiga and Fumie Tanzawa and Shiho Iwasaki and Fumi Inaba and Kosaku Fujiwara and Hayato Iwadare and Tomoki Echigo and Yuji Nakamura and Tomoyuki Shibata and Kanae Suzuki and Isao Yasumatsu and Ayako Nakayama and Yukiko Sasazawa and Etsu Tashiro and Masaya Imoto and Shinichi Kurakata",
year = "2012",
month = "1",
doi = "10.1097/CAD.0b013e32834c6a33",
language = "English",
volume = "23",
pages = "119--130",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17

AU - Kiga, Masaki

AU - Tanzawa, Fumie

AU - Iwasaki, Shiho

AU - Inaba, Fumi

AU - Fujiwara, Kosaku

AU - Iwadare, Hayato

AU - Echigo, Tomoki

AU - Nakamura, Yuji

AU - Shibata, Tomoyuki

AU - Suzuki, Kanae

AU - Yasumatsu, Isao

AU - Nakayama, Ayako

AU - Sasazawa, Yukiko

AU - Tashiro, Etsu

AU - Imoto, Masaya

AU - Kurakata, Shinichi

PY - 2012/1

Y1 - 2012/1

N2 - The mitogen-activated protein kinase (MAPK) signal pathway plays a central role in regulating tumor cell proliferation, survival, and differentiation. The components of this pathway, Ras/Raf/MEK/ERK, are frequently activated in human cancers. Targeting this pathway is considered to be a promising anticancer strategy. In particular, MEK is an attractive drug target because of its high selectivity to ERK. We can expect potent growth inhibitory and proapoptotic effects by inhibiting MEK. Here, we report derivatives of N-[2-(2-chloro-4-iodo- phenylamino)-3,4-difluorophenyl]-methanesulfonamide as novel MEK1/2 inhibitors. Among these compounds, we found SMK-17 to be a potent MEK1/2 inhibitor with high aqueous solubility. The in-silico docking study suggested that SMK-17 is bound to an allosteric pocket of MEK1. The kinetic study and the kinase profiler analysis confirmed the allosteric nature of SMK-17. SMK-17 inhibited MEK1 kinase activity in a non-ATP-competitive manner and it was highly selective to MEK1 and 2. SMK-17 inhibited the growth of tumor cell lines in vitro. Especially, it seemed that cell lines harboring highly phosphorylated MEK1/2 and ERK1/2 were highly sensitive to SMK-17. Moreover, unlike previously reported MEK inhibitors, PD184352 or U0126, SMK-17 did not inhibit the phosphorylation of ERK5. In vivo, SMK-17 exhibited potent antitumor activity in animal models on oral administration. SMK-17 selectively blocked the MAPK pathway signaling without affecting other signal pathways, which resulted in significant antitumor efficacy without notable side effects. These findings suggest that SMK-17, an exquisitely selective, orally available MEK1/2 inhibitor, is a useful chemical biology tool for characterizing the function of MEK/MAPK signaling both in vitro and in vivo.

AB - The mitogen-activated protein kinase (MAPK) signal pathway plays a central role in regulating tumor cell proliferation, survival, and differentiation. The components of this pathway, Ras/Raf/MEK/ERK, are frequently activated in human cancers. Targeting this pathway is considered to be a promising anticancer strategy. In particular, MEK is an attractive drug target because of its high selectivity to ERK. We can expect potent growth inhibitory and proapoptotic effects by inhibiting MEK. Here, we report derivatives of N-[2-(2-chloro-4-iodo- phenylamino)-3,4-difluorophenyl]-methanesulfonamide as novel MEK1/2 inhibitors. Among these compounds, we found SMK-17 to be a potent MEK1/2 inhibitor with high aqueous solubility. The in-silico docking study suggested that SMK-17 is bound to an allosteric pocket of MEK1. The kinetic study and the kinase profiler analysis confirmed the allosteric nature of SMK-17. SMK-17 inhibited MEK1 kinase activity in a non-ATP-competitive manner and it was highly selective to MEK1 and 2. SMK-17 inhibited the growth of tumor cell lines in vitro. Especially, it seemed that cell lines harboring highly phosphorylated MEK1/2 and ERK1/2 were highly sensitive to SMK-17. Moreover, unlike previously reported MEK inhibitors, PD184352 or U0126, SMK-17 did not inhibit the phosphorylation of ERK5. In vivo, SMK-17 exhibited potent antitumor activity in animal models on oral administration. SMK-17 selectively blocked the MAPK pathway signaling without affecting other signal pathways, which resulted in significant antitumor efficacy without notable side effects. These findings suggest that SMK-17, an exquisitely selective, orally available MEK1/2 inhibitor, is a useful chemical biology tool for characterizing the function of MEK/MAPK signaling both in vitro and in vivo.

KW - allosteric inhibition

KW - antitumor activities

KW - cell cycle arrest

KW - kinase inhibitor

KW - xenograft model

UR - http://www.scopus.com/inward/record.url?scp=82555169599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82555169599&partnerID=8YFLogxK

U2 - 10.1097/CAD.0b013e32834c6a33

DO - 10.1097/CAD.0b013e32834c6a33

M3 - Article

C2 - 22008853

AN - SCOPUS:82555169599

VL - 23

SP - 119

EP - 130

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 1

ER -